4 results about "Bilobalides" patented technology

Provided herein are bilobalide derivative compounds, processes for their preparation, methods of use, and uses for the prevention or treatment of nervous system diseases and cancer.

The invention discloses a gene GbCYP701A6 for promoting synthesis of ginkgo terpene lactones and application of the gene GbCYP701A6. The nucleotide sequence of the gene GbCYP701A6 is shown as SEQ ID NO.1, and the amino acid sequence of protein expressed by the gene GbCYP701A6 is shown as SEQ ID NO.2. The invention further discloses a preparation method of the gene GbCYP701A6. According to the invention, a brand new gene GbCYP701A6 is cloned from gingko for the first time. The GbCYP701A6 gene is transferred into a ginkgo biloba body, the GbCYP701A6 gene is over-expressed, the contents of terpene lactones including ginkgolide A, ginkgolide B, ginkgolide C and bilobalide in ginkgo biloba are remarkably increased, and the contents of the ginkgolide A, ginkgolide B, ginkgolide C and bilobalide are remarkably reduced when the gene is silently expressed, so that the gene is a key gene for promoting synthesis of the ginkgo terpene lactones, and the GbCYP701A6 gene can be used for preparing the ginkgo biloba terpene lactones. Therefore, the regulation and control of the expression of the GbCYP701A6 has important application value in the aspects of improving the medicinal quality of the ginkgo leaves and the like.

This invention provides a composition of Ginkgo biloba extract and its preparation method. The composition consists of Ginkgo biloba extract (calculated as total flavonol glycosides) and dipyridamole in a dosage ratio of 10:4. The preparation method can significantly improve product yield, reduce production costs, and significantly increase the content of the main components of the produced Ginkgo biloba extract, namely total flavonol glycosides and terpene lactones. It can also reduce the content of poorly water-soluble ginkgolides and harmful impurities such as ginkgolic acid, control its microbial level, and improve the stability and safety of the Ginkgo biloba extract preparation product of this invention.

The invention discloses application of bilobalide in inhibiting migration and invasion of ovarian cancer cells, and relates to the technical field of biological medicines. Application of bilobalide in preparation of drugs for inhibiting migration and invasion of ovarian cancer cells; the concentration of the bilobalide is 5 [mu] M to 40 [mu] M. In the application of the bilobalide, the bilobalide shows an obvious growth inhibition effect on ovarian cancer cells and has no obvious influence on the survival rate of normal ovarian cells; in a concentration range of 5-40 [mu] M, bilobalide shows dose dependence on activity inhibition of SKOV3 and ID-8 cells, but has small influence on IOSE80 cells, and shows a good safety window; compared with a traditional chemotherapeutic drug, the bilobalide as a natural compound has better biocompatibility, and is expected to be capable of remarkably relieving common toxic and side effects such as myelosuppression and liver and kidney function impairment in clinical application.